Journal info
Aims and Scope |
||
Select Journal
Journals
Acta Virologica Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Neoplasma Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
General Physiology and Biophysics Vol.42, No.2, p. 209–215, 2023 |
||
Title: Ivabradine curbs isoproterenol-induced kidney fibrosis | ||
Author: Tomas Baka, Peter Stanko, Kristina Repova, Silvia Aziriova, Kristina Krajcirovicova, Andrej Barta, Stefan Zorad, Fedor Simko | ||
Abstract: This study investigated whether chronic isoproterenol administration could induce kidney alterations and whether ivabradine, a heart rate (HR)-reducing substance exerting cardiovascular protection, is able to attenuate potential kidney damage. Twenty-eight Wistar rats were divided into non-diseased controls, rats treated with ivabradine, rats treated with isoproterenol, and rats treated with isoproterenol plus ivabradine. Six weeks of isoproterenol administration was associated with decreased systolic blood pressure (SBP) (by 25%) and glomerular, tubulointerstitial and vascular/perivascular fibrosis due to enhanced type I collagen volume (7-, 8-, and 4-fold, respectively). Ivabradine reduced HR (by 15%), partly prevented SBP decline (by 10%) and site-specifically mitigated kidney fibrosis by decreasing type I collagen volume in all three sites investigated (by 69, 58, and 67%, respectively) and the ratio of type I collagen-to-type III collagen in glomerular and vascular/perivascular sites (by 79 and 73%, respectively). We conclude that ivabradine exerts protection against kidney remodelling in isoproterenol-induced kidney damage. |
||
Keywords: Ivabradine — Isoproterenol — Kidney fibrosis — Chronic kidney disease — Cardiorenal syndrome | ||
Published online: 14-Mar-2023 | ||
Year: 2023, Volume: 42, Issue: 2 | Page From: 209, Page To: 215 | |
doi:10.4149/gpb_2022057 |
||
|
![]() |
|